Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2014 / Cilt: 48 - Sayı: 4

Evaluationofskinlesions of lupus with Turkish revised cutaneouserythematosus disease area and severitylupus index

Lupusun deri bulgularının Türkçe revize edilmiş kutane lupus eritematozus hastalık alan ve şiddet indeksi ile değerlendirilmesi

Pages
208–214
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The scores obtained2014; 48: 208-14) from this scale may vary

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is used to evaluate the cutaneous manifestations in patients with lupus erythematosus (LE).
📊
Key Findings & Data:The aim of this study was to increase the clinical use of the RCLASI by translating this scale into Turkish and to evaluate the effects of factors, which affect CLASI, on RCLASI.
💡
Conclusion & Impact:The scores obtained2014; 48: 208-14) from this scale may vary
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is used to evaluate the cutaneous manifestations in patients with lupus erythematosus (LE). In recent years, the Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI) which provides more objective assessment has been developed, but the number of studies utilizing RCLASI are limited. The aim of this study was to increase the clinical use of the RCLASI by translating this scale into Turkish and to evaluate the effects of factors, which affect CLASI, on RCLASI. Materials and Methods: The scale was translated into Turkish by using proper international translation steps. Ninety-three LE patients who were admitted to Trakya University Faculty of Medicine were included in this study. Socio-demographic and clinical characteristics of the patients were recorded. Cutaneous manifestations were calculated using RCLASI. Two scores were obtained: activity and damage scores. The relationship of the scores with patient age, gender, duration of illness, facial involvement, subtypes of LE, and antinuclear antibody, Anti-Ro/ SS-A antibody and Anti-La/SS-B antibody positivities were evaluated. Results: The mean activity and damage scores were 2.59±2.88 and 0.81±1.88, respectively. When activity and damage scores were compared between the age groups, there was no statistically significant difference. The damage scores were significantly higher in male patients than in female patients. The activity scores were statistically significantly higher in patients with disease duration of more than three years and facial involvement. There was no statistically significant difference between the subtypes of LE and the activity and damage scores. RCLASI damage scores were statistically significantly higher in Anti-La/SS-B antibody positive patients. Conclusion: RCLASI is an appropriate scoring system to evaluate the cutaneousdepending on gender, disease duration and presence of facial involvement. (Turkdermmanifestations in patients with LE. The scores obtained2014; 48: 208-14) from this scale may vary

Özet

Amaç: Lupus eritematozuslu (LE) hastaların deri bulgularını değerlendirmek amacıyla kutane lupus eritematozus hastalık alan ve şiddet indeksi (KLASİ) kullanılmaktadır. Son yıllarda daha objektif değerlendirme sağlayan revize edilmiş kutane lupus eritematozus hastalık alan ve şiddet indeksi (RKLASİ) geliştirilmiştir. Ancak ölçeğin kullanımıyla ilgili yeterince çalışma bulunmamaktadır. Bu çalışmadaki amacımız, RKLASİyi Türkçeye çevirerek klinik kullanımını artırmak ve KLASİyi etkileyen faktörlerin RKLASİ üzerindeki etkilerini değerlendirmektir. Gereç ve Yöntem: Ölçek, uluslararası çeviri basamakları izlenerek Türkçeye çevrildi. Trakya Üniversitesi Tıp Fakültesine başvuran toplam 93 LE hastası çalışmaya alındı. Hastaların sosyo-demografik ve klinik özellikleri kayıt edildi. Deri bulguları RKLASİ ile hesaplanarak aktivite ve hasar skoru olmak üzere iki ayrı skor elde edildi. Elde edilen skorlar ile hastaların yaşları, cinsiyetleri, hastalık süreleri, yüz tutulumları, LE alt tipleri ve antinükleer antikor, Anti-Ro/SS-A antikor, Anti-La/SS-B antikor pozitiflikleri arasındaki ilişkiler değerlendirildi. Bulgular: Ortalama aktivite skoru 2,59±2,88, ortalama hasar skoru 0,81±1,88 olarak bulundu. Yaş grupları arasında aktivite ve hasar skoru karşılaştırıldığında anlamlı istatistiksel bir fark saptanmadı. Erkek hastalarda hasar skorunun kadın hastalara göre anlamlı derecede yüksek olduğu gözlendi. Aktivite skoru, hastalık süresi üç yıldan fazla olan hastalar ile yüz tutulumu olan hastalarda istatistiksel olarak anlamlı düzeyde yüksek saptandı. LE alt tipleri ile aktivite ve hasar skoru arasında anlamlı istatistiksel bir fark bulunamadı. RKLASİ hasar skoru Anti-La/SS-B antikor pozitif hastalarda istatistiksel olarak anlamlı düzeyde yüksek saptandı. Sonuç: RKLASİ LEli hastaların deri bulgularını değerlendirmek için kullanılabilecek uygun bir skorlama sistemidir. Bu ölçekte elde edilen skorlar cinsiyete, hastalık süresine ve yüz tutulumu olup olmamasına göre değişkenlik gösterebilmektedir. (Türk­derm 2014; 48: 208-14)

🔖

Cite This Article

GÜRSEL, Y. Ü., PAMUK, Ö. N., ARICAN, Ö., DÖNMEZ, S. (2022). Evaluationofskinlesions of lupus with Turkish revised cutaneouserythematosus disease area and severitylupus index. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 48 - Sayı: 4, 208–214. https://ajindex.com/articles/621836

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Kuhn A, Meuth AM, Bein D, et al: Revised cutaneouslupus erythematosus disease area and severity index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010;163:83-92.
  2. Costner IM, Sontheimer RD: Lupus erythematosus. Fitzpatrick’s Dermatology in General Medicine. Ed. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. 7. Baskı.
  3. NewYork, McGraw-Hill Co, 2008;1515-35. 3. Krathen MS, Dunham J, Gaines E, et al: The cutaneous lupus erythematosus disease activity and severity index: expansion for rheumatology and dermatology. Arthritis Rheum 2008;59:338-44. 4. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. 5. Kundakcı N: Sistemik lupus eritematozus cilt ve mukoza bulguları. Turkiye Klinikleri J Int Med Sci 2005;1:16-25. 6. Gilliam JN, Sontheimer RD: Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981;4:471-5. 7. Sontheimer RD: The lexicon of cutaneous lupus erythematosus-A review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997;6:84-95. 8. Yee CS, McElhone K, Teh LS, Gordon C: Assessment of disease activity and quality of life in systemic lupus erythematosus-New aspects. Best Pract Res Clin Rheumatol 2009;23:457-67. 9. Albrecht J, Taylor L, Berlin JA, et al: The CLASI (Cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889-94. 10. Yokogawa N, Tanikawa A, Amagai M, et al: Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol 2013;23:318-22. 11. Pothinamthong P, Janjumratsang P: A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. J Med Assoc Thai 2012;95:933-40. 12. Cortés-Hernández J, Avila G, Vilardell-Tarrés M, Ordi-Ros J: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012 7;14:265. 13. Erceg A, Bovenschen HJ, van de Kerkhof PC, de Jong EM, Seyger MM: Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermato